SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
FMTX
--
0.00%
--
Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors
Forma Therapeutics announces that Wayne A.I. Frederick, M.D., has been elected to serve on the company’s board of directors
Business Wire · 4d ago
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23)
Benzinga · 07/24 11:15
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22)
Benzinga · 07/23 12:25
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)
Benzinga · 07/21 11:59
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
Benzinga · 07/15 11:30
Credit Suisse Initiates Coverage On Forma Therapeutics Hldgs with Outperform Rating, Announces Price Target of $64
Credit Suisse analyst Tiago Fauth initiates coverage on Forma Therapeutics Hldgs (NASDAQ:FMTX) with a Outperform rating and announces Price Target of $64.
Benzinga · 07/14 09:30
Forma Therapeutics started at outperform with $54 stock price target at SVB Leerink
marketwatch.com · 07/14 06:15
The Week Ahead In Biotech: J&J Kickstarts Pharma Earnings, Repare Therapeutics IPO
Biotech stocks advanced in the week ended July 10 amid mixed news flow emerging out of the sector.
Benzinga · 07/12 15:25
Leaf Group, Forma Therapeutics See Activist Action
Oak Investment Partners disclosed a large stake in digital-content provider Leaf Group. Forma Therapeutics said it owns more than nine million shares of biopharmaceutical firm Forma.
Barrons.com · 07/02 23:30
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Forma Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Forma Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Business Wire · 06/23 20:05
Shares of Forma Therapeutics Open For Trade At $40; IPO Priced At $20 Per Share
Benzinga · 06/19 14:37
Forma Therapeutics Shares To Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m.; IPO Priced At $20/Share
Benzinga · 06/19 14:02
Forma Therapeutics Prices 13.8M Share IPO @$20/Share
Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) announced the pricing of its initial public offering of 13,882,352 shares of common stock at a public offering price of $20.00 per share. All of the shares are being offered by Forma.
Benzinga · 06/19 09:38
Forma Therapeutics Announces Pricing of Initial Public Offering
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the pricing of its initial public offering of 13,882,352 shares of common stock at a public offering
Business Wire · 06/19 01:04